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Abstract
The objective of the paper is to review the literature and provide 
recommendations for use of aminoglycoside antibiotics in criti-
cally ill obese patients. Literature search in PubMed for all articles 
on the use of aminoglycosides in critically ill obese patients was 
conducted, and all articles related to pharmacokinetics in obesity 
were reviewed. Bibliographies of all searched manuscripts were 
also reviewed in an attempt to find additional references. Although 
aminoglycoside pharmacokinetics have been described in detail, 
data on aminoglycoside use and appropriate dose modification in 
critically ill obese patients are very limited. Knowledge on amino-
glycoside pharmacokinetics and use in critically ill obese patients 
is incomplete. Pathophysiologic changes in obesity can result in 
sub- or supra-therapeutic aminoglycoside plasma concentrations, 
especially in the presence of sepsis. Rigorous clinical studies are 
needed to establish aminoglycoside dosing guidelines in critically 
ill obese patients with sepsis.
Keyword: Aminoglycoside; Gentamicin; Amikacin; Tobramycin; 
Obesity; Sepsis; Critical illness; Pharmacokinetics
Introduction
Obesity is a major worldwide health problem, and is associ-
ated with serious diseases and increased morbidity and mor-
tality. Physiologic changes in obesity significantly influence 
antibiotic pharmacokinetic characteristics, including distribu-
tion, protein binding, metabolism and renal excretion. In order 
to reach therapeutic levels, some medications require dosing 
adjustments in obese patients, especially in the presence of 
critical illness. Aminoglycosides act synergistically with other 
antimicrobial agents, and are very important for treatment of 
serious infections. However, because aminoglycoside plasma 
levels can be significantly affected by obesity, due to amino-
glycoside distribution into adipose tissue, dosing modifica-
tion is needed in order to reach therapeutic plasma levels, and 
therapeutic drug monitoring (TDM) has been recommended. 
The aim of this study is to review data on aminoglycoside 
pharmacokinetics in obesity and summarize published data 
regarding the use of aminoglycosides and the need for dose 
modification in critically ill obese patients with sepsis.
Literature Search Methods
We searched for publications relevant to this review, using 
the PubMed database. The initial PubMed search was con-
ducted in September 2012 and was updated in October 2013. 
The search was conducted using the terms “aminoglycosides 
dosing and obesity”, “aminoglycosides pharmacokinetics 
and obesity”, “aminoglycosides in sepsis and obesity” and 
“aminoglycosides pharmacokinetics in sepsis” as keywords. 
We excluded animal studies, and studies published in lan-
guages other than English. There was no exclusion based on 
type of aminoglycoside or publication date. The search in-
cluded all types of articles, including case reports and review 
articles, and the bibliography of all extracted manuscripts 
was reviewed in attempt to identify additional references. All 
articles published in English related to aminoglycoside use 
in obesity were reviewed. When we identified publications 
of overlapping data, we only used data from the newer or 
more detailed publication. Two authors reviewed the abstract 
and text of all articles that seemed relevant to this review.
 
Literature Review
Our literature search revealed 20 articles in the “aminogly-
Manuscript accepted for publication May 6, 2014
aInternal Medicine Department, University Hospital of Patras, Rion 
 26500, Greece
bIntensive Care Department, Brugmann University Hospital, Brussels 
 1030, Belgium
cDepartment of Anesthesiology, Washington University School of 
 Medicine, St. Louis, Missouri, USA
dCorresponding Author: Menelaos Karanikolas, Department of 
 Anesthesiology, Washington University School of Medicine, Campus 
 Box 8054, 660 S. Euclid Ave, St Louis, Missouri, 63110, USA. 
 Email: menelaos.karanikolas@gmail.com; karanikm@wustl.edu
doi: http://dx.doi.org/10.14740/jocmr1858w
   227                                     228
J Clin Med Res. 2014;6(4):227-233Velissaris et al
Articles © The authors   |   Journal compilation © J Clin Med Res and Elmer Press Inc™   |   www.jocmr.org
cosides dosing and obesity” term, 42 articles in the “ami-
noglycosides pharmacokinetics and obesity”, 165 articles in 
the “aminoglycosides pharmacokinetics in sepsis” and seven 
articles in the “aminoglycosides in sepsis and obesity”. We 
then searched for publications with text combining most 
keywords. The combination of the above searches revealed 
a total of 33 articles, case series and letters which were in-
cluded in this review.
Overall, we found very limited data on aminoglycoside 
pharmacokinetics and dose modification in obesity. Four ear-
ly studies on morbidly obese patients, by Schwartz referring 
to gentamicin and tobramycin in 1978 [1], by Blouin refer-
ring to tobramycin in 1979 [2], by Bauer referring to amika-
cin in 1980 [3] and by Korsager referring to gentamicin in 
1980 [4] concluded that morbidly obese patients have larger 
volume of distribution (Vd) compared to normal weight pa-
tients.
Schwartz et al evaluated the pharmacokinetics of genta-
micin and tobramycin and calculated elimination constants 
and volumes of distribution in 13 obese vs. 13 normal weight 
subjects. Their results showed that gentamicin and tobramy-
cin are distributed less to adipose tissue compared to other 
tissues, and mean Vd in obese subjects closely approximates 
the Vd seen in normal subjects, when using normalized body 
mass +40% of adipose mass as total weight in obese subjects 
[1]. Bauer at al studied aminoglycoside pharmacokinetics 
in two matched groups of 30 normal weight vs. 30 obese 
patients with documented Gram negative infection, and con-
cluded that pharmacokinetics are altered in obesity, therefore 
morbidly obese patients require significantly higher genta-
micin, tobramycin or amikacin doses compared to normal 
weight patients [5]. To compensate for increased Vd in obe-
sity, aminoglycoside loading doses can be based on adjusted 
body weight (ABW), which is calculated using the formula: 
ABW = IBW + 0.4 × (TBW - IBW), where IBW is ideal 
body weight, and TBW is total body weight [5]. However, 
these studies were conducted at a time when once-daily anti-
biotic regimens (5 - 7 mg/kg for tobramycin or gentamicin), 
which are popular today, were not widely used. Analysis 
of pharmacokinetic data from 2073 patients (497 receiving 
tobramycin and 1,576 receiving gentamicin) using various 
formulas for Vd, showed that Vd was normalized for both 
tobramycin and gentamicin at all weight categories with use 
of lean body weight (LBW) estimated based as described by 
Table 1. Summary, in Chronological Order, of Studies on Aminoglycoside Pharmacokinetics and Dose Adjustment 
in Obesity
ABW: adjusted body weight; ClCr: creatinine clearance; DWCF: dosing weight correction factor; IBW: ideal body weight; TBW: total 
body weight; Vd: volume of distribution.
Author, year Antibiotic studied Main findings
Schwartz et al, 
1978 [1]
Gentamicin, tobramycin Vd in obese subjects closely approximates Vd in normal subjects 
when using the formula: ABW = IBW + 0.4 × (TBW - IBW)
Blouin et al, 1979 
[2]
Tobramycin Tobramycin loading dose based on ABW = IBW + 0.58 × (TBW - 
IBW)
Korsager, 1980 [4] Gentamicin Gentamicin uptake in adipose tissue = 43.7% of uptake in total 
body mass of normal-weight patients
Bauer et al, 1980 
[3]
Amikacin Amikacin loading dose based on ABW = IBW + 0.38 × (TBW - 
IBW)




Loading dose based on ABW = IBW + 0.4 × (TBW - IBW)
Leader et al, 1994 
[11]
Gentamicin Initial dose based on calculation of ClCr by Cockroft equation with 
IBW + 0.4 × (TBW - IBW)
Traynor et al, 
1995 [8]
Tobramycin The TBW/IBW ratio predicts Vd.
For patients with TBW/IBW ratio ≥ 1.25, doses based on ABW = 
IBW + 0.43 × (TBW - IBW)
Wurtz et al, 1997 
[10]
Aminoglycosides DWCF = 0.4, therefore ABW = IBW + 0.4 × (TBW - IBW)
Pai et al, 2007 
[12]
Aminoglycosides Dosing of aminoglycosides should be based on ABW.
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Janmahasatian et al [6, 7].
In 1995, Traynor et al investigated aminoglycoside phar-
macokinetics in 1,708 patients who received gentamicin and 
tobramycin. Regression analysis revealed that the TBW to 
IBW ratio (TBW/IBW) predicted Vd. Furthermore, there 
were no large differences between dosing weight correcting 
factors (DWCFs) derived from IBW and body mass index 
(BMI)-based classification systems. This study concluded 
that, when calculating aminoglycoside doses, BMI values 
were not better than IBW, and proposed that DWCF for ami-
noglycoside doses should be IBW + 0.43 × EBW (where 
EBW is the excess body weight (EBW = TBW - IBW)) for 
patients with TBW/IBW ratio ≥ 1.25 [8].
In 1997, Wurtz et al published a review on antimicro-
bial pharmacokinetics and dosing in obesity, and proposed 
that, because 30% of adipose tissue is water, a DWCF of 
0.3 should be used. Therefore the weight used to calculate 
doses of hydrophilic antibiotics is derived from the equation: 
IBW + 0.3 × (TBW - IBW), where IBW is derived from the 
Devine formula [9] and TBW is total body weight. However, 
other clinical data suggest that the DWCF is 0.4 for amino-
glycosides [10]. Published data on aminoglycoside DWCFs 
are summarized in Table 1 [1-5, 8, 10-12].
Our search revealed several reports describing physi-
ologic changes in obesity [2, 10, 13, 14]. Because aminogly-
coside dosing in critically ill obese patients has not been ex-
tensively studied, we could only find limited data, including 
a literature review by Erstad, which showed that circulatory 
changes in sepsis affect dosing and pharmacokinetics [15]. 
Data published by Cheymol support modification of loading 
and maintenance doses in critically ill obese patients due to 
physiologic alterations related to sepsis [16]. Although dose 
modification is described in studies by Leader, Corcoran and 
Blouin, appropriate aminoglycoside doses in critically ill 
obese patients are still debated [2, 11, 13, 17].
Regarding existing methods for measuring creatinine 
clearance (ClCr), published data provide accurate estimates 
for patients with normal weight, but not for obese ones. 
Compared to measured ClCr in obese patients, when the 
Cockroft-Gault equation is used with IBW, ClCr is underes-
timated, whereas ClCr is overestimated when TBW is used 
[18]. The Salazar-Corcoran equation, which shows strong 
correlation between ClCr and fat free body mass is as ac-
curate as the Cockroft-Gault equation for the normal weight 
patients, but seems superior when applied to obese patients 
[19]. Therefore, when ClCr is not measured, estimation of 
ClCr using the Salazar-Corcoran equation should improve 
the ability to select appropriate doses for drugs cleared prin-
cipally by renal filtration.
With regard to administration of aminoglycoside main-
tenance doses, most meta-analyses showed that once-daily 
regimens are equal or superior to multiple dose regimens, 




Pathophysiologic changes in obesity affect most hydrophilic 
medications [10, 14, 25]. Because pharmacokinetic altera-
tions in obesity affect absorption, Vd and clearance of many 
antibiotics, estimation of the correct antibiotic dose is of 
critical importance, especially in septic patients with mul-
tiple organ failure, where morbidity and mortality are high. 
However, despite obesity becoming a worldwide problem, 
antibiotic dosing in obese patients has not been studied ad-
equately, and published data are very limited [26].
Morbid obesity alters aminoglycosides pharmacoki-
netics, as both Vd and clearance are increased in morbidly 
obese patients compared to patients with normal weight [16], 
but most published data in obesity refer to drug distribution. 
Pathophysiologic changes in obesity result in altered cardiac 
structure and function with increased cardiac output, altered 
tissue blood flow and increased gut perfusion. However, drug 
absorption does not seem to be altered, and several studies 
evaluating drug absorption did not find differences in obese 
vs. non-obese patients [10, 15]. At the present time, although 
Vd of many drugs, particularly lipophilic ones, is altered in 
obesity, there is no universally accepted factor to estimate 
Vd in obese individuals [27]. Although plasma proteins such 
as a1 acid-glycoprotein and lipoproteins are highly concen-
trated in obesity, binding of drugs to albumin does not seem 
to be altered. Vd of drugs equally soluble in water and oil 
(such as aminoglycosides) is slightly increased in obesity. 
Also, because distribution of a drug between adipose tis-
sue and other tissues influences pharmacokinetics in obese 
patients, loading dose should be adjusted for IBW. Mainte-
nance dosage also needs adjustment, depending on changes 
in drug clearance, as described in several studies on obese 
individuals [16]. Hepatic clearance of many drugs is also al-
tered in obesity, but the metabolic capacity of the liver must 
be reduced > 90% before drug metabolism is significantly 
affected [25, 28].
In conclusion, Vd seems to be the pharmacokinetic vari-
able most affected in obesity, and can be estimated using 
an ABW that includes a fraction of the excess body weight 
(TBW-IBW) [29].
ClCr, a useful measure for approximating glomerular 
filtration rate (GFR), is generally overestimated when it is 
calculated based on TBW, but is generally underestimated 
when based on IBW [2, 10]. The Cockcroft-Gault equation 
can be used to estimate GFR in lean patients, but its use in 
obesity is questionable due to disparity between muscle mass 
and body weight ratio [18]. The Salazar-Corcoran equation 
is an attempt to more accurately estimate ClCr in obesity, 
by taking into account serum creatinine, gender, TBW, age 
and height [19]. A comparison of the Cockroft-Gault vs. the 
Salazar-Corcoran equation showed that prediction of genta-
micin elimination rate constant, clearance and elimination 
half time was best when ClCr was estimated using the Cock-
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roft-Gault equation [11]. However, according to retrospec-
tive studies, the Salazar-Corcoran formula is more precise 
for obese patients [12, 30].
Aminoglycosides (gentamicin, amikacin, tobramycin, 
netilmicin, kanamycin and streptomycin) are cornerstones 
of therapy for serious Gram negative and aerobic bacilli 
infections [31], therefore appropriate aminoglycoside load-
ing and maintenance dosing is important for good outcome. 
When initiating aminoglycoside therapy, a loading dose is 
needed to achieve therapeutic levels quickly. The loading 
dose is very important with aminoglycosides, because a high 
initial dose is needed to maximize their anti-bacterial effect 
and lower mortality [32, 33]. In addition, because aminogly-
coside effect is concentration-dependent, administration of 
maintenance doses using extended interval regimens is pre-
ferred. Loading dose depends on Vd and target plasma con-
centration (Cp), both of which are affected by critical illness: 
Vd is altered in sepsis, due to alterations in microvascular 
permeability and abnormalities of extracellular body water. 
In one prospective study, Vd was estimated to be 0.43 ± 0.12 
L/kg in the beginning of gentamicin therapy, but, as patient 
condition stabilized Vd was reduced to 0.29 ± 0.17 L/kg on 
the seventh day of treatment [34]. Because Vd and drug me-
tabolism change with patient condition, optimization of ami-
noglycoside dosing is difficult in critical illness: hepatic and 
renal failure can affect antibiotic clearance, and critically ill 
patients have increased Vd and variable clearance compared 
to patients with less severe disease [35]. As Vd increases, 
aminoglycoside loading doses need to be increased in sepsis 
[15], and plasma level monitoring (also known as TDM) has 
been recommended to improve safety and effectiveness [34, 
36, 37].
Aminoglycoside dosing in obese critically ill patients is 
even more challenging because drug distribution between 
fat and lean tissue influences pharmacokinetics, therefore 
aminoglycosides, being hydrophilic agents, need dosing ad-
justment. At the present time, there are limited data on the 
effects of fluid changes in critically ill obese ICU patients 
with sepsis [15], but the need for dose adjustment has been 
established for gentamicin, tobramycin and amikacin [2, 11, 
17].
In healthy adults, aminoglycoside Vd is approximately 
0.26 L/kg (range: 0.2 - 0.3). However, aminoglycoside dos-
ing needs modification in obesity using a correcting factor 
of 0.4, because an estimated 40% of the dose is distributed 
into adipose tissue. [11, 15, 17]. Therefore, the equation for 
calculating ABW reads as follows: ABW = IBW + 0.4 × 
(TBW - IBW).
The above dosing modification is very important, be-
cause calculation of aminoglycoside dosing based on TBW 
may result in high serum concentrations, thereby increasing 
the risk for nephrotoxicity and ototoxicity [2, 16] in obesity. 
However, data regarding nephrotoxicity are conflicting, with 
studies on aminoglycoside kinetics showing no significant 
difference between obese patients and patients with normal 
weight with regard to ClCr for gentamicin [11].
Obesity is related to glomerular hyperfiltration, rather 
than to effects on tubular secretion [7]. The Cockcroft-Gault 
[18], the Salazar-Corcoran [19] and the modification of diet 
in renal disease (MDRD) [38] equation are the equations 
most commonly used for estimation of clearance. However, 
although these formulas are widely used, they are not reli-
able estimators of function, particularly in patients with high 
BUN/SCr ratio [39]. Furthermore, the predictive perfor-
mance of newer formulas such as the MDRD and chronic 
kidney disease-epidemiology (CKD-EPI) [40] compared to 
the Cockcroft-Gault equation for assessment of kidney func-
tion and estimation of aminoglycoside clearance in obesity 
is unknown [41]. A study by Pai suggested that the CKD-
EPI equation best predicts aminoglycoside clearance [7]. 
Overall, MDRD provides more reliable estimations of renal 
function compared to the Cockcroft-Gault formula, but both 
formulas lack precision. MDRD is not superior to Cockcroft-
Gault for drug dosing, and MDRD estimated GFR (eGFR) 
needs adjustment to patient’s body surface area for drug 
dosing. Although Cockcroft-Gault has the advantage of sim-
plicity and longer use [42], drug dosing guidelines are often 
based on ClCr estimated using the Cockcroft-Gault equation 
as surrogate for GFR.
Controversy exists with regard to the use of these for-
mulas in obesity: the Cockcroft-Gault equation relies on 
TBW, and therefore overestimates GFR in obese patients. 
Similarly, the MDRD equation, which indexes GFR based 
on a normalized body surface area of mL/min/1.73 m2 also 
overestimates GFR in obese patients.
Aminoglycoside dosing is based on weight, according 
to either of two strategies: traditional, more frequent dos-
ing, vs. extended-interval dosing, but dosing interval should 
be adjusted in patients with renal impairment. According 
to the American Society of Health Systems Pharmacists, 
in patients with normal renal function, traditional dosing 
consists of 1 - 2 mg/kg doses given multiple times per day, 
whereas the newer strategy utilizes 5 - 10 mg/kg every 24 
h. Although aminoglycosides have been administered using 
multiple daily dosing regimens for decades, newer clinical 
and laboratory studies suggest that once-daily dosing confers 
advantages with regard to efficacy [43, 44]. With regard to 
extended interval dosing in obesity, a retrospective analysis 
by Ross suggests that use of DWCF of 40% is accurate [45].
In ICU patients, however, other factors such as sepsis 
and renal dysfunction can significantly alter aminoglycoside 
pharmacokinetics, and individual TDM is warranted [46]. 
Details regarding the effects of fluid shifts on aminoglyco-
side pharmacokinetics have not been well studied in criti-
cally ill obese patients. Finally, the advantages of large once-
daily aminoglycoside doses have been questioned, because 
of apparent pyrogen-mediated toxicity [47]. As relevant pub-
lished data are very limited [47], there is great need for well-
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conducted clinical trials on obese critically ill patients [15].
Understanding of the pathophysiologic changes in obe-
sity and knowledge of the literature on aminoglycosides are 
valuable for rational determination of dosages in obese pa-
tients. As aminoglycosides are first-line drugs in sepsis, there 
is clearly a need for more studies on the appropriate use and 
dosing of aminoglycosides in critically ill obese patients. It 
is important to realize that studies on pharmacokinetics in 
obesity have limitations, such as patient population hetero-
geneity, small patient numbers, the fact that many data are 
referring to single doses rather than ongoing use, and limited 
knowledge on the effects of obesity on pharmacokinetics. 
Failure to appropriately modify doses in obesity can result 
in therapeutic failure or increased toxicity, therefore TDM, 
when feasible, has been recommended in order to optimize 
the safety and effectiveness of aminoglycoside antibiotic 
therapy [37, 48].
Conclusion
Modification of drug dosage in obese patients is very im-
portant, particularly when using medications with narrow 
therapeutic index. Alterations of aminoglycoside pharmaco-
kinetic parameters in obesity may necessitate deviation from 
dosages commonly recommended for non-obese individuals, 
but knowledge on the influence of obesity on pharmacoki-
netics is limited. This review shows that currently available 
literature supports the need for aminoglycoside dosage mod-
ification in critically ill obese patients. Physicians need to 
take every possible step to ensure that aminoglycoside doses 
are adequate and safe. Because pathophysiologic changes 
in obesity can result in sub- or supra-therapeutic concentra-
tions, aminoglycoside doses should be re-evaluated daily in 
critically ill obese patients, and TDM can help optimize ther-
apy. Clinicians prescribing antibiotics for critically ill obese 
patients should be familiar with drug and patient factors in-
fluencing the effectiveness of antibiotic therapy.
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